The notices it replaced
- Reissues: PAR-21-036 NIAMS Clinical Trial Implementation Cooperative Agreement (U01 Clinical Trial Required)
- 2 steps back: PAR-18-594 NIAMS Clinical Trial Implementation Cooperative Agreement (U01 Clinical Trial Required)
- 3 steps back: PAR-16-447 NIAMS Clinical Trial Implementation Cooperative Agreement (U01)
- 4 steps back: PAR-15-165 NIAMS Clinical Trial Implementation Cooperative Agreement (U01)
- 5 steps back: PAR-14-200 NIAMS Clinical Trial Implementation Cooperative Agreement (U01)
- 6 steps back: PAR-11-219 NIAMS Clinical Trial Implementation Cooperative Agreement (U01)
Replaced by PAR-25-141.
Who won it before
32 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $35,401,587 in first-year total cost, median $989,028.
Most frequent study sections
- Arthritis and Musculoskeletal and Skin Diseases Clinical Trials Study Section [AMSC]22
- Special Emphasis Panel[ZAR1 MEP (M2)]3
- Special Emphasis Panel[ZAR1 KM (M2)]2
- Special Emphasis Panel[ZAR1 KS (M2)]2
- Special Emphasis Panel[ZAR1 XZ (M1)]2
Most frequent institutions
- BRIGHAM AND WOMEN'S HOSPITAL5
- CINCINNATI CHILDRENS HOSP MED CTR3
- WAKE FOREST UNIVERSITY3
- JOHNS HOPKINS UNIVERSITY2
- UNIVERSITY OF MICHIGAN AT ANN ARBOR2
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2025 | Anti-CD38 isatuximab Immunotherapy in Hidradenitis Suppurativa: a randomized, double-blinded, placebo-controlled, seamless phase 2a/2b trial1UG3AR085895-01 | ADRIANTO, INDRAMI, QING-SHENGZHOU, LI | HENRY FORD HEALTH + MICHIGAN STATE UNIVERSITY HEALTH SCIENCES, MI | $333,625 | AMSC |
| 2025 | Accelerated Flap Coverage Versus Standard Timing in the Treatment of Severe Lower Extremity Musculoskeletal Injuries1UG3AR085896-01 | GAGE, MARK JOSEPHMUNDY, LILYSPRAGUE, SHEILA | JOHNS HOPKINS UNIVERSITY, MD | $267,527 | AMSC |
| 2024 | A Superiority Trial of Radiofrequency Ablation for Low Back Pain1U01AR084723-01 · under PAR-21-036 | FRIEDLY, JANNA LSURI, PRADEEP | UNIVERSITY OF WASHINGTON, WA | $1,364,600 | AMSC |
| 2023 | The Osteoarthritis Prevention Study (TOPS)1U01AR082121-01 · under PAR-21-036 | MESSIER, STEPHEN P | WAKE FOREST UNIVERSITY, NC | $3,300,332 | ZAR1 |
| 2023 | Treat-to-Target Serum Urate versus Treat-to-Avoid Symptoms in Gout: A Randomized Controlled Trial (TRUST)1U01AR080985-01A1 · under PAR-21-036 | BARRY, MICHAEL JCHOI, HYON KSOLOMON, DANIEL HAL | MASSACHUSETTS GENERAL HOSPITAL, MA | $2,046,055 | AMSC |
| 2023 | Stopping Hydroxychloroquine In Elderly Lupus Disease (SHIELD)1R01AR082149-01 · under PAR-21-036 | BUYON, JILL PIZMIRLY, PETER | NEW YORK UNIVERSITY SCHOOL OF MEDICINE, NY | $1,557,772 | ZAR1 |
| 2023 | Cannabidiol for postoperative Opioid Reduction in primary total Knee arthroplasty – a randomized, 2x2 factorial, double-blind, placebo-controlled clinical trial (The CORK trial)1U01AR083132-01 · under PAR-21-036 | BOEHNKE, KEVIN FOXMANBRUMMETT, CHAD MGAGNIER, JOEL JOSEPH | UNIVERSITY OF MICHIGAN AT ANN ARBOR, MI | $1,275,381 | AMSC |
| 2023 | Autologous Bone Marrow Aspirate Concentrate for the Treatment of Osteonecrosis of the Femoral Head1U01AR080993-01A1 · under PAR-21-036 | GOODMAN, STUART BJONES, LYNNE C.MONT, MICHAEL | JOHNS HOPKINS UNIVERSITY, MD | $779,056 | AMSC |
| 2022 | Methotrexate treatment of Arthritis caused by Chikungunya virus (MARCH): A randomized controlled trial of methotrexate versus placebo in the treatment of chronic arthritis after chikungunya infection1U01AR079717-01A1 · under PAR-21-036 | CHANG, AILEENFIRESTEIN, GARY S | GEORGE WASHINGTON UNIVERSITY, DC | $1,588,967 | AMSC |
| 2022 | The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study1R01AR079124-01A1 · under PAR-21-036 | BRUNNER, HERMINE IDEVARAJAN, PRASADVINKS, ALEXANDER A | CINCINNATI CHILDRENS HOSP MED CTR, OH | $1,255,070 | AMSC |
| 2022 | HIP fracture Accelerated surgical TreaTment And Care tracK-2 (HIP ATTACK-2) trial1U01AR080377-01A1 · under PAR-21-036 | BORGES, FLAVIA KESSLERDEVEREAUX, P.J.SLOBOGEAN, GERARD | UNIVERSITY OF MARYLAND BALTIMORE, MD | $1,004,029 | AMSC |
| 2022 | Knee Arthroplasty Activity Trial (KArAT)1R01AR080346-01A1 · under PAR-21-036 | LOSINA, ELENA | BRIGHAM AND WOMEN'S HOSPITAL, MA | $811,152 | ZAR1 |
| 2022 | Bisphosphonate Use to Mitigate Bone Loss Secondary to Bariatric Surgery1U01AR080969-01 · under PAR-21-036 | ARD, JAMY DBEAVERS, KRISTEN MARIE | WAKE FOREST UNIVERSITY, NC | $660,777 | AMSC |
| 2021 | IMPACCT: Infrastructure for Musculoskeletal Pediatric Acute Care Clinical Trials1U01AR079113-01 · under PAR-18-594 | JANICKI, JOSEPH A | LURIE CHILDREN'S HOSPITAL OF CHICAGO, IL | $1,722,779 | AMSC |
| 2021 | A randomized, double-blind, multi-center comparative effectiveness study of spironolactone versus doxycycline hyclate for the treatment of acne in women1U01AR079752-01 · under PAR-18-594 | MARGOLIS, DAVID | UNIVERSITY OF PENNSYLVANIA, PA | $1,040,468 | AMSC |
| 2020 | SLE Treatment with N-acetylcysteine1U01AR076092-01A1 · under PAR-18-594 | MCDERMOTT, MICHAEL PPERL, ANDRASWALLACE, DANIEL J. | UPSTATE MEDICAL UNIVERSITY, NY | $1,500,000 | ZAR1 |
| 2020 | Knee Arthroplasty AcTivity (KArAT) Trial1U56AR075288-01A1 · under PAR-18-594 | LOSINA, ELENA | BRIGHAM AND WOMEN'S HOSPITAL, MA | $463,259 | ZAR1 |
| 2019 | Clinical Trial for Surgery of the Ulnar Nerve (SUN) at the Elbow1U01AR073485-01A1 · under PAR-18-594 | CHUNG, KEVIN C | UNIVERSITY OF MICHIGAN AT ANN ARBOR, MI | $760,258 | AMSC |
| 2019 | Team-Based Connected Health to Improve Access and Outcomes in Atopic Dermatitis1R01AR073486-01A1 · under PAR-18-594 | ARMSTRONG, APRIL W | UNIVERSITY OF SOUTHERN CALIFORNIA, CA | $725,614 | ZAR1 |
| 2019 | STABILITY 2: ACL Reconstruction +/- Lateral Tenodesis with Patellar vs. Quad Tendon1U01AR076144-01 · under PAR-18-594 | IRRGANG, JAMES JOHNMUSAHL, VOLKER | UNIVERSITY OF PITTSBURGH AT PITTSBURGH, PA | $705,076 | AMSC |
| 2018 | BEAR-MOON: A Two Arm Noninferiority Blinded Randomized Clinical Trial Comparing ACL Repair with BEAR Device vs. Standard of Care Autograft Patellar Tendon ACL Reconstruction1R01AR074131-01 · under PAR-16-447 | SPINDLER, KURT PAUL | CLEVELAND CLINIC LERNER COM-CWRU, OH | $1,363,577 | ZAR1 |
| 2018 | A Community-based Assessment of Skin Care, Allergies, and Eczema: The CASCADE Trial1R01AR071057-01A1 · under PAR-16-447 | SIMPSON, ERIC L | OREGON HEALTH & SCIENCE UNIVERSITY, OR | $974,026 | AMSC |
| 2018 | Lupus Intervention Fatigue Trial (LIFT)1R01AR071091-01A1 · under PAR-16-447 | EHRLICH-JONES, LINDA S.RAMSEY-GOLDMAN, ROSALIND | NORTHWESTERN UNIVERSITY AT CHICAGO, IL | $344,288 | AMSC |
| 2017 | A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy of ManNAc in Subjects with GNE Myopathy1U01AR070498-01A1 · under PAR-15-165 | AMATO, ANTHONY ARNOLDCARRILLO, NURIA | BRIGHAM AND WOMEN'S HOSPITAL, MA | $1,897,534 | AMSC |
| 2017 | Multi-site Randomized Clinical Trial of FIT Teens for Juvenile Fibromyalgia1R01AR070474-01A1 · under PAR-15-165 | KASHIKAR-ZUCK, SUSMITA | CINCINNATI CHILDRENS HOSP MED CTR, OH | $1,766,426 | AMSC |
| 2017 | Study of Anti-Malarials in Incomplete Lupus Erythematosus (SMILE)1U01AR071077-01 · under PAR-15-165 | KARP, DAVID ROLSEN, NANCY J | PENNSYLVANIA STATE UNIV HERSHEY MED CTR, PA | $1,443,698 | AMSC |
| 2017 | Treatment of Meniscal Problems in Osteoarthritis: TeMPO1U01AR071658-01 · under PAR-15-165 | KATZ, JEFFREY NEIL | BRIGHAM AND WOMEN'S HOSPITAL, MA | $797,762 | ZAR1 |
| 2017 | PTH (1-34) and Pelvic Fracture Healing: A Randomized Controlled Trial1U01AR069869-01A1 · under PAR-15-165 | NIEVES, JERI WANZOR | HELEN HAYES HOSPITAL, NY | $458,813 | AMSC |
| 2017 | A Phase I Study of the Safety of AAV2/8 LSPhGAA in Late-onset Pompe Disease1U01AR071693-01 · under PAR-15-165 | KOEBERL, DWIGHT D | DUKE UNIVERSITY, NC | $370,961 | AMSC |
| 2016 | Real-Time Sensorimotor Feedback for Injury Prevention Assessed in Virtual Reality1U01AR067997-01A1 · under PAR-14-200 | MYER, GREGORY DONALD | CINCINNATI CHILDRENS HOSP MED CTR, OH | $698,292 | AMSC |
| 2015 | Weight Loss and Exercise for Communities with Arthritis in North Carolina (WE-CAN)1U01AR068658-01 · under PAR-14-200 | JORDAN, JOANNE M.MESSIER, STEPHEN P | WAKE FOREST UNIVERSITY, NC | $1,160,852 | ZAR1 |
| 2015 | Treatments Against RA and Effect on FDG PET CT: The TARGET TRIAL1U01AR068043-01A1 · under PAR-14-200 | BATHON, JOAN MARIESOLOMON, DANIEL HAL | BRIGHAM AND WOMEN'S HOSPITAL, MA | $963,561 | ZAR1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.